natgillin/translations-raw huggingface dataset:
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Taltz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Taltzi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tasermity’s benefits are greater than its risks for the treatment of hyperphosphataemia and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Tasermity kasulikkus hüperfosfateemia ravis on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the approved doses of Envarsus have been shown to have a comparable quality, safety and effectiveness to Advagraf and Prograf.
Inimravimite komitee otsustas, et Envarsuse heaks kiidetud annustel on ravimitega Advagraf ja Prograf võrreldav kvaliteet, ohutus ja efektiivsus.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Coagadex are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Coagadexi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Giotrif outweigh its risks and recommended that it be granted marketing authorisation in the EU.
Inimravimite komitee otsustas, et Giotrifi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Inductos are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Inductose kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Neparvis are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Neparvise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Obizur are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Obizuri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Omidria are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Omidria kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Ravicti are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ravicti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Raxone are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Raxone kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tivicay’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Tivicay kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Translarna’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Translarna kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Triumeq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Triumeqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Trulicity’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Trulicity kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tybost’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Tybosti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ultibro Breezhaler’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ultibro Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ulunar Breezhaler’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ulunar Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Uptravi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Uptravi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vargatef’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Vargatefi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vaxelis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Vaxelise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Velphoro’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Velphoro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vimizim’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Vimizimi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vitekta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Vitekta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vizamyl’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Vizamyli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vokanamet’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Vokanameti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Voncento’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Voncento kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xadago’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xadago kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xigduo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xigduo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xofigo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xofigo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xoterna Breezhaler’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xoterna Breezhaleri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xtandi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xtandi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xultophy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xultophy kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Xydalba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Xydalba kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zalviso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zalviso kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zavicefta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zavicefta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zerbaxa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zerbaxa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zinbryta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zinbryta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zontivity’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zontivity kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zurampic’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zurampicu kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Zykadia’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zykadia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Abasaglar has been shown to have a comparable quality, safety and effectiveness to Lantus.
Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Abasaglar võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil ravimi Lantus profiiliga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Accofil has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Accofili võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil ravimi Neupogen profiiliga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Bemfola has been shown to have a comparable quality, safety and effectiveness to GONAL-f.
Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Bemfola võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil ravimi GONAL-f profiiliga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Grastofil has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Inimravimite komitee otsustas, et Euroopa Liidu nõuete kohaselt on tõendatud, et Grastofili kvaliteedi, ohutus- ja efektiivsusprofiil on võrreldav võrdlusravimi Neupogeni profiiliga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Inflectra has been shown to have a comparable quality, safety and efficacy profile to Remicade.
Inimravimite komitee otsustas, et Euroopa Liidu nõuete kohaselt on tõendatud, et Inflectra kvaliteedi, ohutuse ja efektiivsuse profiil on võrreldav võrdlusravimi Remicade profiiliga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima has been shown to have a comparable quality, safety and efficacy profile to Remicade.
Inimravimite komitee otsustas, et Euroopa Liidu nõuete kohaselt on tõendatud, et Remsima kvaliteedi, ohutuse ja efektiivsuse profiil on võrreldav võrdlusravimi Remicade profiiliga.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Akynzeo was effective at preventing both the immediate and delayed phases of nausea and vomiting following chemotherapy, and that the medicine has a favourable safety profile.
Inimravimite komitee märkis, et Akynzeo on efektiivne nii keemiaravijärgse iivelduse ja oksendamise kohese kui ka hilise faasi ennetamisel ning et ravimil on soodne ohutusprofiil.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that available data from the main studies, two of which were still ongoing at the time of the evaluation, showed high response rates with Zydelig in patients with chronic lymphocytic leukaemia and follicular lymphoma.
Inimravimite komitee märkis, et põhiuuringute andmed (millest hindamise ajal kaks alles kestis) viitasid suurtele ravivastuse määradele Zydeligi kasutamisel kroonilise lümfotsüütleukeemia ja follikulaarse lümfoomi korral.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Daklinza used in combination with other medicines was shown to be effective against hepatitis C virus, including in patients with genotype 1 resistant to previous treatment.
Inimravimite komitee märkis, et koos teiste ravimitega kasutatud Daklinza osutus C-hepatiidi viiruse vastu efektiivseks, sealhulgas varasemale ravile resistentse 1. genotüübiga patsientidel.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Evarrest was shown to be effective when used to stop bleeding in surgery and the product could be a suitable alternative to other products and techniques.
Inimravimite komitee märkis, et on tõendatud Evarresti efektiivsus verejooksu peatamisel kirurgiliste protseduuride käigus ning et see on olemasolevate vahendite ja meetodite sobiv alternatiiv.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Exviera used in combination with Viekirax is effective in clearing the hepatitis C virus genotypes 1a and 1b from the blood with and without ribavirin.
Inimravimite komitee märkis, et Exviera kombinatsioonravi Viekiraxiga koos ribaviriiniga ja ilma on efektiivne C-hepatiidi 1a ja 1b genotüüpi viiruse eemaldamisel verest.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that HyQvia produces a similar reduction in the number of serious bacterial infections to that seen with other immunoglobulin products, and using recombinant hyaluronidase allows subcutaneous infusions to be given at much longer intervals, although local reactions are slightly more common.
Inimravimite komitee märkis, et HyQvia kasutamisel saavutati raskete bakteriaalsete infektsioonide arvu samasugune vähenemine kui teiste müügiloaga inimese normaalimmunoglobuliinide kasutamisel ja et rekombinantse hüaluronidaasi kasutamine võimaldab manustada nahaaluseid infusioone palju pikemate ajavahemike tagant, ehkki lokaalseid reaktsioone esineb seejuures veidi sagedamini.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Imlygic is a therapy with a novel mechanism of action which can be a valuable addition to existing therapies for advanced inoperable melanoma, an area of unmet medical need.
Euroopa Ravimiameti inimravimite komitee märkis, et Imlygic on uudse toimemehhanismiga ravim, mis võib olla väärtuslik täiendus olemasolevatele kaugelearenenud mitteopereeritava melanoomi ravimitele, mis on vastamata meditsiinilise vajadusega valdkond.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Imvanex is effective at triggering the production of antibodies to a level expected to provide protection against smallpox, although the exact level and duration of protection it would provide in an outbreak is not known.
Inimravimite komitee märkis, et Imvanex on efektiivne antikehade tekitamises tasemel, mis eeldatavasti kaitseb rõugete eest, ehkki kaitse täpne tase ja kestus haiguspuhangu korral ei ole teada.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that paliperidone injections are effective in treating schizophrenia symptoms.
Euroopa Ravimiameti inimravimite komitee märkis, et süstitav paliperidoon on skisofreenia sümptomite ravimisel efektiivne.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Spedra was more effective than placebo in allowing successful intercourse.
Euroopa Ravimiameti inimravimite komitee märkis, et Spedra oli eduka suguühte võimaldamisel platseebost efektiivsem.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that stimulant medicines are first line treatments for ADHD and that these medicines provide a larger and more consistent improvement in ADHD symptoms as part of a comprehensive treatment programme.
Inimravimite komitee märkis, et aktiivsus- ja tähelepanuhäire esmavaliku ravimid on stimulaatorid ning et tervikliku raviprogrammi osana leevendavad need ravimid aktiivsus- ja tähelepanuhäire sümptomeid ulatuslikumalt ja järjekindlamalt.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that studies showed that the use of Lymphoseek led to a higher detection rate for sentinel lymph nodes than the use of vital blue dye.
Euroopa Ravimiameti inimravimite komitee märkis, et uuringute kohaselt võimaldas Lymphoseek tuvastada rohkem valvurlümfisõlmi kui sinine vitaalvärvaine.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that the main study had shown that MACI was superior to microfracture surgery in treating patients with cartilage defects of the knee.
Inimravimite komitee märkis, et põhiuuringu järgi on MACI põlveliigese kõhrekahjustustega patsientide ravis parem kui mikrofraktuurkirurgia.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that the studies had shown that Lonquex is effective in reducing the duration of severe neutropenia and the number of febrile neutropenia cases.
Euroopa Ravimiameti inimravimite komitee märkis, et tehtud uuringute kohaselt oli Lonquex efektiivne raske neutropeenia kestuse lühendamisel ja febriilse neutropeenia juhtude arvu vähendamisel.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that Viekirax in combination with other medicines is effective in clearing the hepatitis C virus genotypes 1a, 1b and 4, including in patients with liver scarring.
Inimravimite komitee märkis, et kombinatsioonis teiste ravimitega on Viekirax efektiivne C-hepatiidi viiruse genotüüpide 1a ja 1b ning 4 eemaldamisel organismist, sh maksakoe sidekoestumisega patsientidel.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that benefits of Sialanar outweigh its risks and recommended that it be granted marketing authorisation in the EU.
Inimravimite komitee järeldas, et Sialanari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimile Euroopa Liidus müügiloa.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Empliciti’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee järeldas seetõttu, et Empliciti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that its benefits are greater than its risks and recommended that it be approved in the EU.
Inimravimite komitee otsustas, et Elocta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Portrazza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee järeldas, et Portrazza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.